PressReleases
Press Releases
Kineta Press Releases
SEATTLE, March 22, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
SEATTLE, March 08, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
SEATTLE, March 06, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address
SEATTLE, March 01, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to
Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA —
Seattle, WA — (December 1, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation
Seattle, WA — (November 29, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation
Seattle, WA – (November 15, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation
Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 BOSTON, Nov. 10,
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.